Deferasirox 180 MG Oral Granules — RxCUI 1923828
RxNorm drug concept · Semantic clinical drug
RxCUI 1923828
Semantic clinical drug · SCD
● Current RxNorm concept 24 FDA products
24 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1923828
Official nameDeferasirox 180 MG Oral Granules
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped24
Package NDCs mapped24
Reported Medicaid activity (SDUD)1,795 prescriptions · 11 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Deferasirox: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It removes extra iron that builds up in the body. That can happen after many blood transfusions, or in certain thalassemia conditions where you don't need regular transfusions. You...
- You take it by mouth once a day, as a tablet, a tablet mixed in liquid, or granules, depending on your product. Your dose depends on your weight and kidney function. Follow your pr...
- Deferasirox can affect your kidneys, liver and blood counts, sometimes seriously. Tests catch problems early, and ferritin checks help make sure your iron isn't removed too far. Pl...
- Diarrhea, nausea, vomiting, stomach pain and rash are common. Call your doctor right away for yellow skin or eyes, black or bloody stools, severe stomach pain, big changes in urina...
🕸️ Concept Web — How Deferasirox 180 MG Oral Granules Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Deferasirox 180 MG Oral Granules
RxCUI 1923828 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Deferasirox
614373IN
-
Deferasirox
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Jadenu
1607785BN
-
Jadenu
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Deferasirox Oral Granules
1923821SCDF -
Deferasirox Granule Product
1923820SCDG -
Deferasirox Oral Product
1157197SCDG -
Deferasirox Oral Granules [Jadenu]
1923823SBDF -
Jadenu Granule Product
1923824SBDG -
Jadenu Oral Product
1607788SBDG -
Oral Granules
317690DF -
Granule Product
1294708DFG - +1 more in this family
-
Deferasirox Oral Granules
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Deferasirox 180 MG
1607781SCDC -
Deferasirox 180 MG Oral Granules [Jadenu]
1923829SBD -
Deferasirox 180 MG [Jadenu]
1607786SBDC
-
Deferasirox 180 MG
Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Deferasirox 180 MG
SCDC · 1607781 -
Deferasirox Oral Granules
SCDF · 1923821 -
Deferasirox Granule Product
SCDG · 1923820 -
Deferasirox Oral Product
SCDG · 1157197
Brand-Name Concepts
-
Deferasirox 180 MG Oral Granules [Jadenu]
SBD · 1923829 -
Deferasirox 180 MG [Jadenu]
SBDC · 1607786 -
Deferasirox Oral Granules [Jadenu]
SBDF · 1923823 -
Jadenu Granule Product
SBDG · 1923824 -
Jadenu Oral Product
SBDG · 1607788 -
Jadenu
BN · 1607785
📦 FDA Products & Package NDCs
24 products · 24 package NDCs
24 package NDCs map to RxCUI 1923828 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00078-0654-15 | 30 TABLET, FILM COATED in 1 BOTTLE (0078-0654-15) | Jadenu | Novartis Pharmaceuticals Corporation | 2015-03-30 |
| 00078-0655-15 | 30 TABLET, FILM COATED in 1 BOTTLE (0078-0655-15) | Jadenu | Novartis Pharmaceuticals Corporation | 2015-03-30 |
| 00078-0656-15 | 30 TABLET, FILM COATED in 1 BOTTLE (0078-0656-15) | Jadenu | Novartis Pharmaceuticals Corporation | 2015-03-30 |
| 00078-0713-15 | 30 PACKET in 1 CARTON (0078-0713-15) / 1 GRANULE in 1 PACKE... | Jadenu | Novartis Pharmaceuticals Corporation | 2017-05-18 |
| 00078-0720-15 | 30 PACKET in 1 CARTON (0078-0720-15) / 1 GRANULE in 1 PACKE... | Jadenu | Novartis Pharmaceuticals Corporation | 2017-05-18 |
| 00078-0727-15 | 30 PACKET in 1 CARTON (0078-0727-15) / 1 GRANULE in 1 PACKE... | Jadenu | Novartis Pharmaceuticals Corporation | 2017-05-18 |
| 31722-0029-32 | 30 PACKET in 1 CARTON (31722-029-32) / 1 GRANULE in 1 PACKE... | DEFERASIROX | Camber Pharmaceuticals, Inc. | 2023-03-16 |
| 31722-0030-32 | 30 PACKET in 1 CARTON (31722-030-32) / 1 GRANULE in 1 PACKE... | DEFERASIROX | Camber Pharmaceuticals, Inc. | 2022-09-22 |
| 31722-0031-32 | 30 PACKET in 1 CARTON (31722-031-32) / 1 GRANULE in 1 PACKE... | DEFERASIROX | Camber Pharmaceuticals, Inc. | 2022-09-22 |
| 42806-0371-30 | 30 PACKET in 1 CARTON (42806-371-30) / 1 GRANULE in 1 PACKE... | Deferasirox Oral Granules | EPIC PHARMA, LLC | 2022-10-06 |
| 42806-0372-30 | 30 PACKET in 1 CARTON (42806-372-30) / 1 GRANULE in 1 PACKE... | Deferasirox Oral Granules | EPIC PHARMA, LLC | 2022-10-06 |
| 42806-0373-30 | 30 PACKET in 1 CARTON (42806-373-30) / 1 GRANULE in 1 PACKE... | Deferasirox Oral Granules | EPIC PHARMA, LLC | 2022-10-06 |
| 59651-0447-30 | 30 PACKET in 1 CARTON (59651-447-30) / 1 GRANULE in 1 PACKE... | DEFERASIROX | Aurobindo Pharma Limited | 2025-09-08 |
| 59651-0448-30 | 30 PACKET in 1 CARTON (59651-448-30) / 1 GRANULE in 1 PACKE... | DEFERASIROX | Aurobindo Pharma Limited | 2025-09-08 |
| 59651-0449-30 | 30 PACKET in 1 CARTON (59651-449-30) / 1 GRANULE in 1 PACKE... | DEFERASIROX | Aurobindo Pharma Limited | 2025-09-08 |
| 67877-0675-84 | 30 PACKET in 1 CARTON (67877-675-84) / 1 GRANULE in 1 PACKE... | Deferasirox oral | Ascend Laboratories, LLC | 2020-07-16 |
| 67877-0676-84 | 30 PACKET in 1 CARTON (67877-676-84) / 1 GRANULE in 1 PACKE... | Deferasirox oral | Ascend Laboratories, LLC | 2020-07-16 |
| 67877-0677-84 | 30 PACKET in 1 CARTON (67877-677-84) / 1 GRANULE in 1 PACKE... | Deferasirox oral | Ascend Laboratories, LLC | 2020-07-16 |
| 69097-0550-53 | 30 PACKET in 1 CARTON (69097-550-53) / 1 GRANULE in 1 PACKE... | Deferasirox | Cipla USA Inc. | 2022-02-23 |
| 69097-0560-53 | 30 PACKET in 1 CARTON (69097-560-53) / 1 GRANULE in 1 PACKE... | Deferasirox | Cipla USA Inc. | 2022-02-23 |
| 69097-0570-53 | 30 PACKET in 1 CARTON (69097-570-53) / 1 GRANULE in 1 PACKE... | Deferasirox | Cipla USA Inc. | 2022-02-23 |
| 72205-0075-30 | 30 PACKET in 1 CARTON (72205-075-30) / 1 GRANULE in 1 PACKE... | Deferasorox | Novadoz Pharmaceuticals LLC | 2021-03-18 |
| 72205-0076-30 | 30 PACKET in 1 CARTON (72205-076-30) / 1 GRANULE in 1 PACKE... | Deferasorox | Novadoz Pharmaceuticals LLC | 2021-03-18 |
| 72205-0176-30 | 30 PACKET in 1 CARTON (72205-176-30) / 1 GRANULE in 1 PACKE... | Deferasorox | Novadoz Pharmaceuticals LLC | 2022-05-21 |
Observed labelers:
Novartis Pharmaceuticals Corporation (6) ·
Ascend Laboratories, LLC (3) ·
Aurobindo Pharma Limited (3) ·
Camber Pharmaceuticals, Inc. (3) ·
Cipla USA Inc. (3) ·
EPIC PHARMA, LLC (3)
· +1 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.